PROFESSOR P.R. FLATT
`BSc, PhD, DSc, CBiol, FBS, CChem, FRSC, FHEA, MRIA
`
`Peter Raymond FLATT
`British
`Professor of Biomedical Sciences and Director Biomedical Research
`School of Biomedical Sciences, Ulster University, Coleraine, Northern
`Ireland, BT52 1SA, U.K. (pr.flatt@ulster.ac.uk; 028-70-124419)
`
`BSc Biology and Chemistry (Aston University; First Class Honours)
`PhD (Aston University) RIA of insulin and glucagon with studies on
`obesity-diabetes in mice. External examiner: Professor CN Hales, FRS
`DSc (Ulster University) Gut hormones and peptide therapeutics for
`diabetes
`
`Royal Society European Exchange Postdoctoral Research Fellow
`Department of Medical Cell Biology, University of Uppsala, Sweden
`Role Ca2+ in pancreatic beta cell signal transduction- Professor B Hellman
`Lecturer/Senior Lecturer
`Department of Biochemistry, University of Surrey, Guildford
`Professor of Biomedical Sciences and Head of Diabetes Research Group,
`School of Biomedical Sciences, Ulster University
`Director, Biomedical Sciences Research Centre, Ulster University
`Head of School of Biomedical Sciences, Ulster University
`Course Director, Ulster BSc (Hons) Biomedical Science Degree Courses
`Director Biomedical Sciences Research Institute, Ulster University
`
`Elected Fellow of the Institute of Biology (FIBiol now FBS)
`Elected Fellow of the Royal Society of Chemistry (FRSC)
`Recipient of Mary Jane Kugal Award of Juvenile Diabetes Federation
`International
`Recipient of Biochemistry Medal of Irish Section of the Biochemical
`Society
`Elected Member of the Royal Irish Academy (MRIA) – Ireland’s premier
`Learned Body for Sciences and Humanities, founded in 1785
`Awarded Ulster University Senior Distinguished Research Fellowship
`Dorothy Hodgkin Award Lecturer of Diabetes UK
`Niall O’Meara Lecturer of Irish Endocrine Society
`Ernst-Friedrich Pfeiffer Memorial Lecture, European Association for the
`Study of Diabetes (AIDPIT)
`Steno Rounds Medal, Steno Diabetes Centre, Denmark
`
`
`1992-1994
`
`1994-1997
`
`2012-2017
`2017-present
`
`Professional Qualifications and Awards
`
`1989
`1989
`1999
`
`
`Personal
`
`
`Name:
`
`Nationality:
`
`Position
`Work address
`
`
`Education
`
`1971-1974
`1974-1977
`
`2018
`
`
`
`
`
`
`
`
`
`Employment
`
`
`1978-1979
`
`
`
`
`
`
`
`1980-1989
`
`
`
`1989-present
`
`
`
`
`
`
`
`
`
`2006
`
`2006
`
`2006
`2007
`2009
`2010
`
`2016
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`MPI EXHIBIT 1021 PAGE 1
`
`

`

`2017
`2022
`
`
`
`
`
`
`
`Elected Fellow of Higher Education Academy (FHEA)
`2nd ranking Worldwide Expert in Experimental Diabetes and 3rd in Insulin
`Secretion according to independent assessment by Expertscape
`
`
`Research Leadership
`
`
`• Since 1989 responsible for several hundred of research workers, including academic
`staff, postdoctoral research fellows, research assistants, postgraduate research students
`and technical staff.
`• Lead Ulster to award grade 4 in 1992 UFC Research Assessment Exercise under Unit of
`Assessment 11 and highest possible rating of 5* in 1996 RAE. 5* awarded in 2001 and
`2008 REF, with ranking in both 2014 and 2021 within the top 2-6 UK Universities in
`Biomedical Sciences.
`• Founding Head Diabetes Research Group at Ulster University that currently comprises
`10 academic staff, 4 postdoctoral fellows and 12 PhD students.
`• 96 PhD students supervised to successful completion within 4 years of registration
`• 26 Past doctoral students currently hold tenured academic positions in UK or overseas
`and still actively pursue diabetes research.
`
`
`Research and Publications
`
`Original and world-leading experimental diabetes research on gut hormones, peptide
`therapeutics, drug discovery, cell therapy, beta-cell stimulus-secretion coupling and islet cell
`function has substantially advanced knowledge and generated significant interest from industry,
`resulting in publication (with >25,369 citations (h-index 75) of the following:
`
`
`• 4 Multi-author edited international research texts
`• 6 Edited proceedings
`• 111 Reviews and book chapters
`• 571 Original peer-reviewed scientific papers
`• 493 Refereed conference abstracts
`• 25 Patent families and inventions
`
`
`Research discoveries
`
`These include but are not restricted to the following examples with potential translational impact.
`
`
`• Stable analogues of apelin, xenin, PYY, oxytocin, AVP, and esculentin-Cha for obesity-
`diabetes therapy
`• Multiple acting peptide agonists for treatment of obesity-diabetes
`Incretin peptides for prevention of bone fractures and treatment of bone fragility
`•
`• Peptide analogues of GIP for treatment of obesity, insulin resistance and diabetes
`• Gut peptide mimetics for treatment of disorders with dysfunctional synaptic transmission
`• Novel GIP antagonist peptides for treatment of metabolic disease
`• Glycated insulin as biomarker for prediabetes
`• Electrofusion derived pancreatic beta cells for drug discovery and cellular screening
`- distributed worldwide by ECACC to >100 research laboratories and licenced following
`evaluation by 5 multi-national pharmaceutical companies
`• Two related Impact Case Studies included in 2014 Ulster REF submission, rated 4*
`
`MPI EXHIBIT 1021 PAGE 2
`
`

`

`
`Research Funding and Commercial Exploitation
`
`
`• Research funding of over £25M from industry and a variety of other sources including
`Diabetes UK, The Wellcome Trust, European Fund for Study of Diabetes (EFSD),
`European Commission, Invest Northern Ireland, SAAD Trading Company, NI
`Department of Health & Social Services, SPUR, DENI, DEL and Ulster University.
`• Academic Founder, Director and CSO of Diabetica Ltd, a company registered in
`Northern Ireland under number NI 33135.
`• Winners of the prestigious 2008 inaugural Academic Enterprise Awards (ACES) Europe
`for Life Sciences for development of new approaches to diabetes therapy.
`Inventor on patents licensed through Innovation Ulster promising staged payments worth
`up to $40M.
`
`•
`
`
`Research Presentations
`
`
`• Approximately 600 research papers presented at national/international conferences
`organised by learned societies in more than 20 countries in Europe, North America,
`Middle East, Asia and Japan.
`• Approximately 100 invited lectures delivered, including many to industry since 1982
`
`
`Membership of Professional Associations
`
`
`• Diabetes UK, European Association for the Study of Diabetes (EASD), Irish Endocrine
`Society, America Diabetes Association (ADA), Royal Irish Academy (RIA)
`
`
`Other Indicators of Esteem and Work Promoting Science
`
`
`• Member, Royal Irish Academy Advisory Committee for Assessment New Candidates
`• Scientific Secretary, Committee of Medical and Scientific Section of British Diabetic
`Association
`• Associate Editor, Frontiers of Endocrinology (Gut Endocrinology Section)
`• Member of Diabetes UK Advisory and Professional Councils, and Diabetes UK
`Research Advisory Group
`• Member Council EASD and EASD Langerhans Fellowship Committee
`• Founding Chairman of EASD Islet Study Group
`• UK Coordinator of EU funded Islet Research European Network (IREN) an Executive
`Committee of EU funded Islet Research European-Latin American Network (IRELAN)
`• Member of Steering Committee of EASD Incretin Study Group
`• Committee member Biochemical Society, Nutrition Society and Liaison Committees of
`British Endocrine Societies
`• Member of Executive Committee and Honorary Treasurer Northern Ireland HPSS RRG
`in Endocrinology & Diabetes
`• Member (or Chairman) Programme and Abstract Review Committees of Diabetes UK,
`EASD, Biochemical Society, Nutrition Society and ADA
`• Member of Grants Review Committee of Diabetes UK and the RD Lawrence Fellowship
`and PhD studentship award committees.
`• Chairperson of EFSD (Metabolic Toxicity) Grants Awards Committee and member of
`Grants Committee for Juvenile Diabetes Research Foundation (JDRF).
`
`MPI EXHIBIT 1021 PAGE 3
`
`

`

`• Member MRC Expert Review Panel on UK Nutrition Research Partnership for Health
`and Disease
`• Referee/advisor for grants submitted to The Wellcome Trust, MRC, Diabetes UK, EFSD,
`JDRF, Diabetes Research & Wellness Foundation (DRWF) plus many others.
`• Member of Editorial Boards: Frontiers in Endocrinology (Associate Editor), Biochemical
`Journal, Journal of Endocrinology, International Journal of Peptides, World Journal of
`Diabetes
`• Regular referee for Diabetes, Diabetologia, Diabetes Obesity Metabolism, Science,
`Nature, Molecular Cellular Endocrinology amongst others
`• External examiner for the Medical Sciences Course (MSC) at the Faculty of Medicine
`and Health Sciences at United Arab Emirates (UAE) University, Al Ain. UAE.
`
`
`National and International Profile
`
`External examiner for 56 PhD theses in the field of islet and gut hormone research for 28
`different Universities in UK, Europe, North America and Asia.
`
`Established contacts with more than 350 scientists from 21 countries worldwide maintained
`through established networks, including EASD Islet Study Group, IREN and IRELAN. Joint
`research and publications with following:
`
`
`Institute of Clinical Biochemistry, Hannover Medical School, Germany (Prof S Lenzen).
`•
`• Department of Endocrinology, Karolinska Institute, Stockholm (Prof P-O Berggren).
`• Oxford Centre for Diabetes Endocrinology & Metabolism, University of Oxford, UK
`(Prof P Rorsman)
`• Bone Research Group, University of Angers, France (Dr G Mabilleau)
`• Research Division, Bangladesh Institute of Research and Rehabilitation in Diabetes,
`Endocrine and Metabolic Disorders, Dhaka (Prof AK Azad Kahn & Prof L Ali).
`• Metabolic Unit, Royal Victoria Hospital, Belfast (Professor PM Bell).
`• Department of Medicine, University of Barcelona, Spain (Prof R Gomis).
`• Laboratory of Experimental Medicine, Brussels Free University, Belgium (Prof WJ
`Malaisse).
`• School of Biomedical and Life Sciences, University of Lancaster (Prof C Holscher).
`• Department of Biomedical Sciences, Curtin University, Perth, Australia (Prof P
`Newsholme).
`
`
`Learning and Teaching
`
`Considerable effort has been devoted to educating the next generation of scientists. Many of
`these have been inspired to become PhD students and gone on to develop successful careers in
`academia or industry. Teaching and related administrative responsibilities include:
`
`
`• Teaching to University BSc (Hons) students studying Biomedical Sciences, Nutrition,
`Optometry, Pharmacy, Biological Sciences; MSc Biomed Sciences and Human
`Nutrition.
`• Course Director, full-time and part-time BSc (Hons) courses in Biomedical Sciences
`(Ulster, 2011- 2017).
`• Course Director, full-time and part-time MSc courses related to Biomedical Sciences
`(Ulster, 1989-1992).
`
`MPI EXHIBIT 1021 PAGE 4
`
`

`

`PROFESSOR PETER R FLATT
`
`EDITED BOOKS
`
`
`Bailey, C.J. and Flatt, P.R. (Eds)
`New Antidiabetic Drugs.
`(49 contributors from 12 countries worldwide)
`Smith Gordon & Co Ltd, London, p 320, 1990.
`
`Flatt, P.R. (Ed)
`Nutrient Regulation of Insulin Secretion.
`(46 contributors from 8 countries worldwide)
`Portland Press, London, p 415, 1992.
`
`Flatt, P.R. and Lenzen, S. (Eds)
`Frontiers of Insulin Secretion and Pancreatic B-Cell Research.
`(240 contributors from 12 countries worldwide)
`Smith-Gordon & Co Ltd, London, p. 630, 1994.
`
`Ioannides, C. and Flatt, P.R. (Eds)
`Drugs, Diet and Disease, Vol. 2, Mechanistic Approaches to Diabetes.
`(33 contributors from 7 countries worldwide)
`Ellis Horwood Ltd, Chichester, p. 380, 1999
`
`
`EDITED PROCEEDINGS AND COLLECTIONS
`
`Flatt, P.R. (Ed)
`Nutrient Regulation of Insulin Secretion.
`Special Colloquium of Biochemical Society, Guildford.
`Biochem. Soc. Trans. 18: 101-127, 1990.
`
`Flatt, P.R. (Ed)
`Molecular mechanisms of insulin secretion and pancreatic B-cell dysfunction.
`Special Colloquium of Biochemical Society, Belfast.
`Biochem. Soc. Trans. 22: 1-41, 1994.
`
`Flatt, P.R. (Ed)
`Hypothalamic and metabolic effects of regulatory peptides.
`Special Colloquium of Biochemical Society, Aberdeen.
`Biochem. Soc. Trans. 24: 559-598, 1996.
`
`Flatt PR and Conlon JM (Eds)
`Newer peptide-based agents for treatment of patients with type 2 diabetes
`Peptides 100: 1-281; 2018.
`
`Flatt PR and Conlon JM (Eds)
`Glucose-dependent insulinotropic polypeptide (GIP)
`Peptides 125; 2020.
`
`Flatt PR, Knopp FK, Tarasov AI (Eds)
`Proglucagon-derived peptides
`Front Endocrinol (Lausanne). 2021, e-book, Nov 11;12:776871. doi:
`10.3389/fendo.2021.776871. PMID: 34858346; PMCID: PMC8631785.
`
`
`1.
`
`2.
`
`3.
`
`4.
`
`
`
`1.
`
`
`
`
` 2.
`
`
`
`
`3.
`
`
`
`
`4.
`
`
`
`5.
`
`
`6.
`
`
`
`
`
`
`
`
`
`
`
`MPI EXHIBIT 1021 PAGE 5
`
`

`

`
`
`PROFESSOR PETER R FLATT
`
`REVIEWS AND BOOK CHAPTERS
`
`
`
`
`Hellman, B., Andersson, T., Berggren, P.-O., Flatt, P.R., Gylfe, E. and Kohnert, K.-D.
`The role of calcium in insulin secretion.
`In: Hormones and Cell Regulation, Vol 3, Eds. J.E. Dumont and J. Nunez.
`Elsevier/North Holland Biomedical Press: Amsterdam, New York and Oxford, pp 69-96,
`1979.
`
`Hellman, B., Abrahamsson, H., Andersson, T., Berggren, P.-O., Flatt, P.R. and Gylfe, E.
`Participation of calcium pools in insulin secretion.
`In: Diabetes 1979, Proceedings of the 10th Congress of the International Diabetes Federation,
`Vienna, September 9-14, 1979. International Congress Series No 500. Ed. W.K Waldhausl,
`Exerpta Medica: Amsterdam, Oxford & Princeton, pp 160-165, 1980.
`
`Hellman, B., Abrahamsson, H., Andersson, T., Berggren, P.-O., Flatt, P.R., Gylfe, E. and
`Hahn, H.-J.
`Calcium movements in relation to glucose-stimulated insulin secretion.
`In: Biochemistry and Biophysics of the Pancreatic B-Cell. European Workshop, Brussels,
`1979. Eds. W.J. Malaisse and I.-B. Taljedal, Georg Thieme Verlag: Stuttgart and New York,
`pp 122-130, 1980.
`
`Marks, V. and Flatt, P.R.
`Nutrition and Metabolism.
`In: Scientific Foundations of Anesthesia, Edn. 3. Eds. C. Scurr and S. Feldman. William
`Heinemann Medical Books Ltd, pp 330-338, 1982.
`
`Bailey, C.J. and Flatt, P.R.
`Obesity: a case for biochemical manipulation.
`Industrial Biotechnology 1: 6-7, 1982.
`
`Bailey, C.J. and Flatt, P.R.
`Advances in insulin therapy.
`Pulse 43: 45-47, 1983.
`
`Bailey, C.J. and Flatt, P.R.
`Recent progress in diabetes.
`Industrial Biotechnology 2: 11-12, 1983.
`
`Flatt, P.R. and Bailey, C.J.
`Neural involvement in the insulin response to feeding in obese hyperglycaemic (ob/ob) mice.
`In: Lessons from Animal Diabetes, Eds. E. Shafrir and A. Renold, John Libbey and Company
`Ltd, London, pp 341-347, 1984.
`
`Flatt, P.R., Bailey, C.J., Swanston-Flatt, S.K., Best, L., Kwasowski, P., Buchanan, K.D. and
`Marks, V.
`Involvement of glucagon and GIP in the metabolic abnormalities of obese hyperglycaemic
`(ob/ob) mice.
`In: Lessons from Animal Diabetes, Eds. E. Shafrir and A. Renold, John Libbey and Company
`Ltd, London, pp 341-347, 1984.
`
`1.
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`9.
`
`MPI EXHIBIT 1021 PAGE 6
`
`

`

`11.
`
`12.
`
`13.
`
`15.
`
`10.
`
`
`Flatt, P.R. and Bailey, C.J.
`Dietary modulation of glucose intolerance in spontaneous obesity and diabetes.
`In: Animal Models for Nutrition Research, Report of the Fifth Ross Conference on Medical
`Research. Ed. R.W. Phillips, Ross Laboratories: Ohio, pp 33-37, 1984.
`
`Bailey, C.J. and Flatt, P.R.
`Animal models of diabetes.
`In: Recent Advances in Diabetes, Vol 2. Ed. M. Nattrass, Churchill Livingstone: Edinburgh,
`pp 71-89, 1986.
`
`Bailey, C.J. and Flatt, P.R.
`Antidiabetic drugs: New developments.
`Industrial Biotechnology 6: 139-142, 1986.
`
`Bailey, C.J. and Flatt, P.R.
`The enteroinsular axis in models of hyperinsulinaemic and hypoinsulinaemic diabetes.
`In: Frontiers in Diabetes Research: Lessons from Animal Diabetes, Vol 2. Eds. E. Shafrir and
`A. Renold, John Libbey and Company Ltd, London, pp 217-224, 1988.
`
`14. Morgan, L.M., Flatt, P.R. and Marks, V.
`Nutrient regulation of the enteroinsular axis and insulin secretion.
`Nutrition Research Review 1: 79-97, 1988.
`
`Bailey, C.J., Flatt, P.R. and Marks, V.
`Drugs inducing hypoglycaemia.
`Pharmac. Ther. 42: 361-384, 1989.
`
`16. Marks, V. and Flatt, P.R.
`The metabolism of sugar and starches.
`In: Dietary Starches and Sugars in Man.
`Ed. J. Dobbing, Springer-Verlag, Berlin, pp 135-149, 1989.
`
`Bailey, C.J. and Flatt, P.R.
`Recent developments in the treatment of diabetes.
`In: Resources and Applications of Biotechnology: The New Wave.
`Ed. R. Greenshields, Macmillan Press Ltd, London, pp 239-252, 1989.
`
`Flatt, P.R. (Ed)
`Nutrient Regulation of Insulin Secretion.
`Biochem. Soc. Trans. 18: 101-127, 1990.
`
`Bailey, C.J. and Flatt, P.R.
`Models for testing new hypoglycaemic drugs.
`In: New Antidiabetic Drugs, Eds. C.J. Bailey and P.R. Flatt, Smith-Gordon and Company
`Ltd, London, pp 65-82, 1990.
`
`Bailey, C.J. and Flatt, P.R.
`Alkylglycidates.
`In: New Antidiabetic Drugs, Eds. C.J. Bailey and P.R. Flatt, Smith-Gordon and Company
`Ltd, London, pp 231-236, 1990.
`
`Bailey, C.J. and Flatt, P.R.
`Animal models of non-insulin dependent diabetes mellitus.
`In: Textbook of Diabetes, Eds. J. Pickup and G. Williams, Blackwell Scientific Publications,
`
`17.
`
`18.
`
`19.
`
`20.
`
`21.
`
`MPI EXHIBIT 1021 PAGE 7
`
`

`

`22.
`
`23.
`
`24.
`
`25.
`
`26.
`
`27.
`
`
`28.
`
`29.
`
`30.
`
`31.
`
`32.
`
`Oxford, pp 228-242, 1991.
`
`Ioannides, C., Barnett, C.R., Ayrton, A.D. and Flatt, P.R.
`Alterations of chemical toxicity in animal models of insulin-dependent diabetes.
`In: Frontiers in Diabetes Research: Lessons from Animal Diabetes, Vol 3.
`Ed. E. Shafrir, Smith-Gordon and Company Ltd, London, pp 306-312, 1991.
`
`Bailey, C.J., Flatt, P.R., Wilcock, C. and Day, C.
`Antihyperglycaemic mechanism of action of metformin.
`In: Frontiers in Diabetes Research: Lessons from Animal Diabetes, Vol 3.
`Ed. E. Shafrir, Smith-Gordon and Company Ltd, London, pp 277-282, 1991.
`
`Swanston-Flatt, S.K., Day, C., Flatt, P.R. and Bailey C.J.
`Evaluation of the antihyperglycaemic properties of traditional plant treatments for diabetes.
`In: Frontiers in Diabetes Research: Lessons from Animal Diabetes, Vol 3.
`Ed. E. Shafrir, Smith-Gordon and Company Ltd, London, pp 286-293, 1991.
`
`Flatt, P.R., Barnett, C.R., Shibier, O. and Swanston-Flatt, S.K.
`Direct and indirect actions of nutrients in the regulation of insulin secretion from the
`pancreatic B-cells.
`Proc. Nutr. Soc. 50: 559-566, 1991.
`
`Swanston-Flatt, S.K., Flatt, P.R., Day, C. and Bailey, C.J.
`Traditional dietary adjuncts for the treatment of diabetes mellitus.
`Proc. Nutr. Soc. 50: 641-651, 1991.
`
`Flatt, P.R. and Bailey, C.J.
`Molecular mechanisms of insulin secretion and insulin action.
`J. Biol. Educ. 25: 9-14, 1991.
`
`Berggren, P.-O., Rorsman, P., Efendic, S., Ostenson, C.G., Flatt, P.R., Nilsson, T.,
`Arkhammar, P. and Juntti-Berggren, L.
`Mechanisms of action of enteroinsular hormones, islet peptides and neural input on the
`insulin secretory process.
`In: Nutrient Regulation of Insulin Secretion, Ed. P.R. Flatt, Portland Press Ltd, London, pp
`289-318, 1992.
`
`Flatt, P.R., Bailey, C.J., Berggren, P.-O., Herberg, L. and Swanston-Flatt, S.K.
`Defective insulin secretion in diabetes and insulinoma.
`In: Nutrient Regulation of Insulin Secretion, Ed. P.R. Flatt, Portland Press Ltd, London, pp
`341-386, 1992.
`
`Flatt, P.R.
`Insulin: Jewel in the Pancreas.
`Biochemist, 14: 12-14, 1992.
`
`Barnett, C.R., Flatt, P.R. and Ioannides, C.
`Interrelationships between insulin-dependent diabetes mellitus and enhanced toxicity to
`environmental chemicals, drugs and carcinogens.
`In: Food, Nutrition and Chemical Toxicity, Eds. D.V. Parke, C. Ioannides and R. Walker,
`Smith-Gordon and Co Ltd, London, pp 161-170, 1993.
`
`Flatt, P.R. and Barnett, C.R.
`Endocrine pancreatic hormones.
`In: Encyclopaedia of Food Science, Food Technology and Nutrition, Vol. 4, Eds. R. Macrae,
`
`MPI EXHIBIT 1021 PAGE 8
`
`

`

`R. Robinson and M. Sadler, Academic Press Ltd, London, pp 2402-2407, 1993.
`
`Barnett, C.R. and Flatt, P.R.
`Ketone bodies.
`In: Encyclopaedia of Food Science, Food Technology and Nutrition, Vol. 4, Eds. R. Macrae,
`R. Robinson and M. Sadler, Academic Press Ltd, London, pp 2622-2626, 1993.
`
`Bailey, C.J. and Flatt, P.R.
`Islet defects and insulin resistance in models of obese non-insulin dependent diabetes.
`Diabetes Metabolism Reviews 9 (Suppl. 1): 43S-50S, 1993.
`
`Flatt, P.R. (Ed)
`Molecular mechanisms of insulin secretion and pancreatic B-cell dysfunction.
`Biochem. Soc. Trans. 22: 1-41, 1994.
`
`Barnett, C.R., Flatt, P.R., Bone, A.J. and Ioannides, C.
`Hepatic cytochrome P450 profile in BB rats with spontaneous insulin-dependent diabetes
`mellitus.
`In: Biochemistry, Biophysics and Molecular Biology of Cytochrome P450. Ed. M.C.
`Lechner, John Libbey Eurotext Ltd., London, pp. 547-550, 1994.
`
`Flatt, P.R., Abdelwahab, Y.H.A., Wilson, A.M., Barnett, C.R., O'Harte, F.P.M. and
`Swanston-Flatt, S.K.
`Site-specific defects and glucose toxicity in pancreatic B-cell dysfunction of non-insulin-
`dependent diabetes mellitus.
`In: Frontiers of Insulin Secretion and Pancreatic B-Cell Research.
`Eds. P.R. Flatt and S. Lenzen, Smith-Gordon and Co Ltd, London, pp. 481-489, 1994.
`
`Strain, J.J., McDermott, B.M., Bailey, C.J. and Flatt, P.R.
`Trace mineral levels in the tissues of streptozotocin-diabetic and obese hyperglycaemicmice.
`In: Trace Elements in Health and Disease with Special Emphasis on Atherosclerosis. Ed.
`M.F. Reis, Smith-Gordon and Co Ltd, London, pp. 225-226, 1995.
`
`Barnett, C.R., Flatt, P.R. and Ioannides, C.
`Drug metabolism and chemical toxicity in diabetes mellitus.
`In: Trends in Comparative Biochemistry and Physiology,
`Ed. J. Menon, Council of Scientific Research Integration, Research Trends, Trivandrum,
`India, pp. 973-984, 1995.
`
`Ioannides, C., Barnett, C.R., Irizar, A. and Flatt. P.R.
`Drug metabolism and chemical toxicity in diabetes.
`In: Drugs, Diet and Disease, vol. 2, Mechanistic Approaches to Diabetes.
`Eds. C. Ioannides and P.R. Flatt, Ellis Horwood Ltd, Chichester, pp. 327-358, 1995.
`
`Bailey, C.J. and Flatt. P.R.
`Development of antidiabetic drugs.
`In: Drugs, Diet and Disease, vol. 2, Mechanistic Approaches to Diabetes.
`Eds. C. Ioannides and P.R. Flatt, Ellis Horwood Ltd, Chichester, pp. 279-326, 1995.
`
`Flatt, P.R. (Ed)
`Hypothalamic and metabolic effects of regulatory peptides.
`Biochem. Soc. Trans. 24: 559-598, 1996.
`
`Ioannides, C., Barnett, C.R., Irizar, A. and Flatt, P.R.
`Expression of cytochrome P450 proteins in disease.
`
`33.
`
`34.
`
`35.
`
`36.
`
`37.
`
`38.
`
`39.
`
`40.
`
`41.
`
`
`42.
`
`
`
`43.
`
`
`MPI EXHIBIT 1021 PAGE 9
`
`

`

`
`
`In: Cytochrome P450: Metabolic and Toxicological Aspects. Ed. C. Ioannides, CRC Press,
`Boca Raton, pp. 301-327, 1996.
`
`
`44. Wilson, A.M., Barnett, C.R. and Flatt, P.R.
`
`Altered secretory responsiveness of BRIN-BD11 cells cultured under hyperglycaemic
`conditions is not readily reversed by subsequent culture in lower glucose concentrations.
`In: Physiology and Pathophysiology of the Islets of Langerhans.
`Ed. B. Soria, Plenum Press, New York, pp. 379-384, 1997.
`
`
`
`
`45.
`
`
`
`
`46.
`
`
`
`Bailey, C.J. and Flatt, P.R.
`Animal syndromes of non-insulin-dependent diabetes mellitus.
`In: Textbook of Diabetes, 2 edn., Eds. J. Pickup and G. Williams, Blackwell Scientific
`Publications, Oxford, pp 23.1-23.25, 1997.
`
`Flatt, P.R.
`Hormonal and neural control of endocrine pancreatic function.
`In: Textbook of Diabetes, 2 edn., Eds. J. Pickup and G. Williams, Blackwell Scientific
`Publications, Oxford, pp 9.1-9.17, 1997.
`
`Flatt, P.R., Abdel-Wahab, Y.H.A., Boyd, A.C., Barnett, C.R. and O'Harte, F.P.M.
`Pancreatic B-cell dysfunction and glucose toxicity in non-insulin-dependent diabetes.
`Proc. Nutr. Soc. 56: 243-262, 1997.
`
`Gray, A.M. and Flatt, P.R.
`Nature's own pharmacy: the diabetes perspective.
`Proc. Nutr. Soc. 56: 507-517, 1997.
`
`
`47.
`
`
`
`48.
`
`
`
`49. McClenaghan, N.H. and Flatt, P.R.
`
`Engineering cultured insulin-secreting pancreatic B-cell lines.
`
`J. Molec. Med.77: 235-243, 1999.
`
`50.
`
`
`Ioannides, C., Barnett, C.R. and Flatt, P.R.
`The effects of experimental diabetes on the cytochrome P450 system and other metabolic
`pathways.
`In: Experimental Models of Diabetes. Ed. J.H. McNeill,
`CRC Press, Boca Raton, pp 79-116, 1999.
`
`
`
`
`51. McClenaghan, N.H. and Flatt, P.R.
`
`Physiological and pharmacological regulation of insulin release - insights offered through
`exploitation of insulin-secreting cell lines.
`Diabetes, Obesity & Metabolism 1: 137-150, 1999.
`
`
`
`52.
`
`
`
`
`
`
`53.
`
`
`
`Salgado, A.P., Santos, R.M., Pereira, F.C., Fernandes, A.P., Tome, A.R., Flatt, P.R.,
`Ranasamy, R. and Rosario, L.M.
`Glucose signalling in clonal insulin-secreting BRIN-BD11 cells: Role of Cytosolic Ca2+ and
`redox state.
`In: Molecular Mechanisms of Transcellular Signalling, Ed. J.P. Thierry, IOS Press,
`Amsterdam, pp 212-220, 1999.
`
`Bailey, C.J. and Flatt, P.R.
`Animal syndromes resembling type 2 diabetes.
`In: Textbook of Diabetes, Eds. J.C. Pickup and G. Williams, 3rd Edn, Blackwell Scientific
`Publications, Oxford, pp 25.1-25.30, 2003.
`
`MPI EXHIBIT 1021 PAGE 10
`
`

`

`54.
`
`Flatt, P.R.
`The hormonal and neural control of endocrine pancreatic function.
`In: Textbook of Diabetes, Eds. J.C. Pickup and G. Williams, 3rd Edn, Blackwell Scientific
`Publications, Oxford, pp 11.1-11.21, 2003.
`
`
`55. McClenaghan, N.H. and Flatt, P.R.
`
`Hormones of the endocrine pancreas.
`
`In: Encyclopedia of Food Sciences and Nutrition, Eds. B. Caballero, L. Trugo and P. Finglas,
`2nd Edn., Academic Press, London, pp. 3150-3157, 2003.
`
`
`56.
`
`
`
`57.
`
`
`58.
`
`
`59.
`
`
`60.
`
`
`61.
`
`
`62.
`
`63.
`
`64.
`
`
`65.
`
`
`
`66.
`
`Gault, V.A., Flatt, P.R. and O’Harte, F.P.M.
`Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential.
` Neuropeptides 37: 253-263; 2003.
`
`Gault, V.A., Flatt, P.R. and O’Harte, F.P.M.
`Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for
`the treatment of obesity-diabetes.
`Biochem. Biophys. Res. Comm. 308: 207-213; 2003.
`
`Furman, B.L., Pyne, N., Flatt, P.R. and O’Harte, F.P.M.
`Targeting beta cell cyclic adenosine monophosphate for the development of novel drugs for
`type 2 diabetes mellitus.
`J. Pharm. Pharmacol., 56: 1-16; 2004.
`
`Green, B.D., Gault, V.A., O’Harte, F.P.M. and Flatt, P.R.
`Structurally modified analogues of glucagon-like peptide 1 (GLP-1) and glucose-dependent
`insulinotropic polypeptide (GIP) as future antidiabetic agents.
`Curr. Pharm. Des. 10: 3651-3662; 2004
`
`Green, B.D., Irwin, N., Gault, V.A., O’Harte, F.P.M. and Flatt, P.R.
`Development and therapeutic potential of incretin hormone analogues for type 2 diabetes.
`Br. J. Diab. Vasc. Dis. 5: 134-140; 2005.
`
`Green, B.D., Flatt, P.R. and Bailey, C.J.
`Inhibition of dipeptidyl peptidase IV activity as potential therapy of type 2 diabetes mellitus.
`Expert Opin. Investig. Drugs, 11: 525-539; 2006.
`
`Flatt, P.R. and Green, B.D.
`Nutrient regulation of insulin secetion in diabetes: Problems and potential solutions.
`Biochem. Soc. Trans. 34: 774-778; 2006.
`
`Green, B.D., Flatt, P.R. and Bailey, C.J.
`Dipeptidyl peptidase IV (DPPIV) inhibitors: A newly emerging drug class for the treatment
`of type 2 diabetes.
`Diab. Vasc. Dis. Res. 3: 159-165; 2006.
`
`Green, B.D., Flatt, P.R. and Bailey, C.J.
`Gliptins: dipeptidyl peptidase-4 (DPP-4) inhibitors to treat type 2 diabetes.
`Future Prescriber 8: 7-13; 2007.
`
`Green, B.D. and Flatt, P.R.
`Incretin hormone mimetics and analogues in diabetes therapeutics.
`Best Pract. Res. Clin. Endocrinol. Metab. 21: 497-516; 2007.
`
`Flatt, P.R., Bailey, C.J and Green B.D.
`
`MPI EXHIBIT 1021 PAGE 11
`
`

`

`Dipeptidyl peptidase IV (DPPIV) and related molecules in type 2 diabetes.
`Front. Biosci. 13: 3648-3660; 2008.
`
`Flatt, P.R.
`Dorothy Hodgkin Lecture 2008: Gastric inhibitory polypeptide (GIP) revisited – a new
`therapeutic target for obesity-diabetes?
`Diabetic Med. 25: 759-764; 2008.
`
`
`68. McKillop, AM., Flatt PR.
`Recent developments in the search for biomarkers for the diagnosis and monitoring of
`diabetes.
`Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2(3):172-177; 2008.
`
`
`67.
`
`
`69.
`
`
`70.
`
`
`71.
`
`
`72.
`
`
`73.
`
`
`
`74.
`
`
`75.
`
`
`76.
`
`
`77.
`
`Irwin, N., Flatt, P.R. and Gault, V.A.
`GIP-based therapeutics for diabetes and obesity.
`Current Chemical Biology 2: 61-68, 2008.
`
`Flatt, P.R., Bailey, C.J. and Green, B.D.
`Recent advances in antidiabetic drug therapies targeting the enteroinsular axis.
`Curr. Drug Metab. 10: 125-137; 2009.
`
`Irwin, N., Moodley, M., Flatt, P.R.
`Maximising the therapeutic potential of glucagon-like peptide-1 in type 2 diabetes.
`Br. J. Diabetes Vasc. Dis. 9 : 44-52 ; 2009.
`
`Irwin, N. and Flatt, P.R.
`Therapeutic potential for GIP receptor agonists and antagonists.
`Best Pract. Res. Clin. Endocrinol. Metab. 23: 499-512; 2009.
`
`Flatt, P.R., Day, C. and Bailey, C.J.
`Bariatric surgery to treat diabesity.
`Br. J. Diabetes Vasc. Dis. 9: 103-107; 2009.
`
`Irwin, N. and Flatt, P.R.
`Evidence for beneficial effects of compromised GIP action in obesity-diabetes and possible
`therapeutic implications.
`Diabetologia 52: 1724-1731; 2009.
`
`Irwin N, Gault VA and Flatt PR.
`Therapeutic potential of the original incretin hormone GIP: Diabetes, Obesity, Osteoporosis
`and Alzheimer’s Disease.
`Expert Opin. Investig. Drugs 19: 1039-1048; 2010.
`
`Bailey, C.J., Green, B.D. and Flatt,P.R.
`Fixed-dose combination therapy for type 2 diabetes: Sitagliptin plus pioglitizone.
`Expert Opin. Investig. Drugs 19: 1017-1025; 2010.
`
`Green, B.D., Bailey, C.J. and Flatt, P.R.
`Gliptin therapies for inhibiting dipeptidyl peptidase-4 in type 2 diabetes.
`European Endocrinol. 6: 26-30; 2010.
`
`
`78. McKillop, A.M. and Flatt, P.R.
`Emerging applications of genomic and metabolic profiling in diabetic clinical medicine.
`Diabetes Care 34: 2624-2630; 2011.
`
`
`MPI EXHIBIT 1021 PAGE 12
`
`

`

`Kelly, C., McClenaghan, N.H. and Flatt, P.R.
`Role of islet structure and cellular interactions in the control of insulin secretion.
`Islets, 3: 41-47; 2011.
`
`Abed A, Critchlow C, Flatt PR, McClenaghan NH and Kelly C.
`Directed differentiation of progenitor cells towards an islet cell phenotype.
`Am. J. Stem Cells 1(3): 196-204; 2012.
`
`Ojo, O. O., Flatt, P. R, Abdel-Wahab, Y. H. A and Conlon, J. M.
`Insulin-releasing peptides.
`In: Handbook of Biologically Active Peptides, Section: Amphibian Skin Peptides, Ed.
`A.Kastin, 2nd Edn, Elsevier Academic Press: Amsterdam. pp. 364-370, 2013.
`
`Irwin N and Flatt PR
`Gastric inhibitory polypeptide (GIP).
`In: Handbook of Biologically Active Peptides, Section: Gastrointestinal Peptides, Ed.
`A.Kastin, 2nd Edn, Elsevier Academic Press: Amsterdam. pp. 1227-1235, 2013.
`
`Irwin, N. and Flatt, P.R.
`Enteroendocrine hormone mimetics for the treatment of obesity and diabetes.
`Curr Opin Pharmacol. 13: 989-995; 2013.
`
`Conlon, J.M., Mechkarska, M., Lukic, M.L. and Flatt, P.R.
`Potential therapeutic applications of multifunctional host-defense peptides from frog skin as
`anti-cancer, anti-viral, immunomodulatory, and anti-diabetic agents.
`Peptides. 57: 67-77; 2014.
`
`Irwin, N. and Flatt, P.R.
`New perspectives on exploitation of incretin peptides for treatment of diabetes and related
`disorders.
`World J. Diabetes 6(215): 1285-1295; 2015.
`
`Flatt PR and Conlon JM
`Newer peptide-based agents for treatment of patients with type 2 diabetes (Editorial)
`Peptides 100: 1-2; 2018.
`
`Conlon J.M., Mechkarske M., Abdel-Wahab, Y.H.A. and Flatt, P.R.
`Peptides from frog skin with potential for development into agents for type 2 diabetes
`therapy.
`Peptides, 100: 275-281; 2018.
`
`Pathak V., Flatt, P.R. and Irwin, N.
`Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of type 2
`diabetes and obesity.
`Peptides, 100: 229-235; 2018.
`
`79.
`
`
`80.
`
`
`81.
`
`
`
`82.
`
`
`83.
`
`
`84.
`
`
`85.
`
`
`88.
`
`
`
`89.
`
`
`90.
`
`
`
`
`86. Mabilleau, G., Chappard, D., Flatt, P.R. and Irwin, N.
`
`Effects of antidiabetic drugs on bone metabolism.
`
`Expert Rev Endocrinol. Metab. 10: 663-675; 2015.
`
`87. Moran, B.M., Flatt, P.R. and McKillop, A.M.
`G-protein coupled receptors: signalling and regulation by lipid agonists for improved glucose
`homeostasis.
`Acta Diabetologica, 53: 177-188; 2016.
`
`MPI EXHIBIT 1021 PAGE 13
`
`

`

`Pathak V, Flatt PR and Irwin N
`The entero-insular axis – contribution to obesity-diabetes and its treatment.
`In Nutrition and Diabetes: Pathophysiology and management. Ed Opara EC, 2n d Edn., CRC
`Press, Boca Raton, 2018.
`
`Kahn D, Moffett CR, Flatt PR and Kelly C
`Role of intra-islet peptides in beta cell regulation and therapy.
`Peptides, 100: 212-218; 2018.
`
`Lafferty R, Flatt PR and Irwin N
`Emerging therapeutic potential of peptide YY for obesity-diabetes.
`Pancreas, 100: 269-274; 2018.
`
`Conlon JM, Moffett RC, Leprince J and Flatt